NO982481L - Fremgangsmater og blandinger for diagnose og behandling av kreft - Google Patents

Fremgangsmater og blandinger for diagnose og behandling av kreft

Info

Publication number
NO982481L
NO982481L NO19982481A NO982481A NO982481L NO 982481 L NO982481 L NO 982481L NO 19982481 A NO19982481 A NO 19982481A NO 982481 A NO982481 A NO 982481A NO 982481 L NO982481 L NO 982481L
Authority
NO
Norway
Prior art keywords
methods
treatment
diagnosis
cancer
compositions
Prior art date
Application number
NO19982481A
Other languages
English (en)
Norwegian (no)
Other versions
NO982481D0 (no
Inventor
Gary L Clayman
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of NO982481D0 publication Critical patent/NO982481D0/no
Publication of NO982481L publication Critical patent/NO982481L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO19982481A 1995-11-30 1998-05-29 Fremgangsmater og blandinger for diagnose og behandling av kreft NO982481L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US781095P 1995-11-30 1995-11-30
PCT/US1996/019083 WO1997020047A1 (en) 1995-11-30 1996-11-27 Methods and compositions for the diagnosis and treatment of cancer

Publications (2)

Publication Number Publication Date
NO982481D0 NO982481D0 (no) 1998-05-29
NO982481L true NO982481L (no) 1998-07-29

Family

ID=21728237

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19982481A NO982481L (no) 1995-11-30 1998-05-29 Fremgangsmater og blandinger for diagnose og behandling av kreft

Country Status (19)

Country Link
US (3) US20020077313A1 (cs)
EP (1) EP0863984B1 (cs)
JP (1) JP2000501394A (cs)
KR (1) KR19990071795A (cs)
CN (2) CN1308450C (cs)
AT (1) ATE325872T1 (cs)
AU (1) AU722042B2 (cs)
CA (1) CA2238829A1 (cs)
CZ (1) CZ296810B6 (cs)
DE (1) DE69636120T2 (cs)
DK (1) DK0863984T3 (cs)
ES (1) ES2264145T3 (cs)
HU (1) HUP9902068A3 (cs)
NO (1) NO982481L (cs)
NZ (1) NZ324168A (cs)
PL (1) PL186018B1 (cs)
RU (1) RU2174409C2 (cs)
SK (1) SK70598A3 (cs)
WO (1) WO1997020047A1 (cs)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022588A2 (en) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
RU2219553C2 (ru) * 2001-10-18 2003-12-20 Ростовский научно-исследовательский онкологический институт Способ определения эффективности аутогемохимиотерапии рака ректосигмоидного отдела прямой кишки и сигмовидной кишки, а также аутогемохимиотерапии в сочетании с свч-гипертермией рака прямой кишки
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
US20040106184A1 (en) * 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US20050032728A1 (en) * 2002-12-17 2005-02-10 Sidney Kimmel Cancer Center Tumor suppression through bicistronic co-expression of p53 and p14ARF
CN1756569A (zh) * 2002-12-27 2006-04-05 印屈根治疗学股份有限公司 增生性病损中乳头瘤病毒和致癌原转化细胞的p53治疗
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
RU2392319C2 (ru) * 2003-03-06 2010-06-20 Жаохи ПЕНГ Рекомбинантный вирус, построенный с использованием вектора вируса и гена-подавителя опухоли человека, а также его применение
RU2234099C1 (ru) * 2003-03-18 2004-08-10 Российская медицинская академия последипломного образования Способ дифференциальной диагностики стадий канцерогенеза
RU2242936C1 (ru) * 2003-04-21 2004-12-27 Ростовский научно-исследовательский онкологический институт Способ лечения рака легкого
EP1721007A2 (en) * 2004-02-23 2006-11-15 Novartis AG P53 wild-type as biomarker for the treatment with mtor inhibitors in combination with a cytotoxic agent
CA2557326A1 (en) * 2004-02-24 2005-09-09 Introgen Therapeutics, Inc. Combination of ad-p53 and chemotherapy for the treatment of tumours
CN100333797C (zh) * 2005-01-26 2007-08-29 彭朝晖 重组腺病毒p53制品在肿瘤治疗中的新用途
RU2245551C1 (ru) * 2004-04-23 2005-01-27 Белохвостов Александр Сергеевич Способ диагностики онкологических заболеваний
RU2263494C1 (ru) * 2004-06-08 2005-11-10 ГУ НИИ глазных болезней РАМН Способ моделирования меланомы роговицы
RU2410098C2 (ru) * 2004-08-31 2011-01-27 Новартис Аг Применение мидостаурина для лечения желудочно-кишечных стромальных опухолей
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
CN102580084B (zh) * 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
JP2008528621A (ja) * 2005-01-27 2008-07-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 腎細胞ガンを処置するための方法
US7327306B2 (en) * 2005-05-06 2008-02-05 Orthosoft Inc. RF system for tracking objects
WO2007090125A2 (en) * 2006-01-30 2007-08-09 Introgen Therapeutics, Inc. Prognostic factors for anti-hyperproliferative disease gene therapy
EP2097517B1 (en) 2006-10-16 2014-06-04 Genelux Corporation Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
US20090081639A1 (en) * 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
RU2371202C2 (ru) * 2007-07-30 2009-10-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ радионуклидной диагностики рака молочной железы
AU2009206225B2 (en) 2008-01-25 2015-04-23 Multivir Inc. p53 biomarkers
US8314068B2 (en) * 2008-04-14 2012-11-20 University Hospitals Of Cleveland P2X7 inhibition of epithelial cancers and papillomas
US20120052003A9 (en) * 2008-05-16 2012-03-01 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy
US20110294870A1 (en) * 2008-12-04 2011-12-01 Opko Curna, Llc Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
RU2384845C1 (ru) * 2008-12-18 2010-03-20 ФГУП Государственный научно-исследовательский институт особо чистых биопрепаратов ФМБА Способ диагностики онкологических заболеваний
PL2391638T3 (pl) * 2009-02-02 2018-11-30 Glaxosmithkline Biologicals Sa Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
RU2395234C1 (ru) * 2009-07-24 2010-07-27 Учреждение Российской Академии Наук Институт Молекулярной Биологии Им. В.А. Энгельгардта Ран (Имб Ран) ОПРЕДЕЛЕНИЕ СНИЖЕНИЯ УРОВНЯ мРНК ГЕНА ZG16 КАК СПОСОБ ДИАГНОСТИКИ РАКА ТОЛСТОЙ КИШКИ И НАБОР ДЛЯ ЕГО ОСУЩЕСТВЛЕНИЯ
WO2012051567A2 (en) 2010-10-15 2012-04-19 The Trustees Of Columbia University In The City Of New York Obesity-related genes and their proteins and uses thereof
WO2012061537A2 (en) 2010-11-02 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
ES2733211T3 (es) 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
CN102352368B (zh) * 2011-09-29 2013-12-04 苏州大学 Ing4与osm双基因共表达载体及其应用
EP2788489B1 (en) * 2011-12-08 2017-03-15 Virovek, Inc. Vectors harboring toxic genes, methods and uses therefor
CN104169850B (zh) 2012-01-12 2017-06-06 辛纳普蒂克斯公司 单层电容性成像传感器
BR112014020103A2 (pt) * 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
EP2968551B1 (en) 2013-03-15 2021-05-05 The Trustees of Columbia University in the City of New York Fusion proteins and methods thereof
WO2014158965A1 (en) * 2013-03-27 2014-10-02 Ge Healthcare As Method and reagent for preparing a diagnostic composition
EP3010519B1 (en) * 2013-06-18 2021-04-07 Dnatrix Inc. Oncolytic adenovirus for use in a treatment of brain cancer
US9552089B2 (en) 2013-08-07 2017-01-24 Synaptics Incorporated Capacitive sensing using a matrix electrode pattern
US9298325B2 (en) 2013-09-30 2016-03-29 Synaptics Incorporated Processing system for a capacitive sensing device
US20150091842A1 (en) 2013-09-30 2015-04-02 Synaptics Incorporated Matrix sensor for image touch sensing
US10042489B2 (en) 2013-09-30 2018-08-07 Synaptics Incorporated Matrix sensor for image touch sensing
US9459367B2 (en) 2013-10-02 2016-10-04 Synaptics Incorporated Capacitive sensor driving technique that enables hybrid sensing or equalization
US9274662B2 (en) 2013-10-18 2016-03-01 Synaptics Incorporated Sensor matrix pad for performing multiple capacitive sensing techniques
US9081457B2 (en) 2013-10-30 2015-07-14 Synaptics Incorporated Single-layer muti-touch capacitive imaging sensor
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
US9798429B2 (en) 2014-02-28 2017-10-24 Synaptics Incorporated Guard electrodes in a sensing stack
CN104357408A (zh) * 2014-03-13 2015-02-18 哈尔滨博翱生物医药技术开发有限公司 一种重组新城疫病毒及其应用
US10133421B2 (en) 2014-04-02 2018-11-20 Synaptics Incorporated Display stackups for matrix sensor
US9927832B2 (en) 2014-04-25 2018-03-27 Synaptics Incorporated Input device having a reduced border region
US9690397B2 (en) 2014-05-20 2017-06-27 Synaptics Incorporated System and method for detecting an active pen with a matrix sensor
DK3201234T3 (en) 2014-09-30 2019-02-25 Diadem S R L ANTIBODY BINDING A LINEAR EPITOP OF HUMAN P53 AND DIAGNOSTIC APPLICATIONS THEREOF
EP3925979A3 (en) 2014-12-23 2022-03-23 The Trustees of Columbia University in the City of New York Fgfr-tacc fusion proteins and methods thereof
US10175827B2 (en) 2014-12-23 2019-01-08 Synaptics Incorporated Detecting an active pen using a capacitive sensing device
US10795471B2 (en) 2015-01-05 2020-10-06 Synaptics Incorporated Modulating a reference voltage to perform capacitive sensing
US9939972B2 (en) 2015-04-06 2018-04-10 Synaptics Incorporated Matrix sensor with via routing
US9715304B2 (en) 2015-06-30 2017-07-25 Synaptics Incorporated Regular via pattern for sensor-based input device
US10095948B2 (en) 2015-06-30 2018-10-09 Synaptics Incorporated Modulation scheme for fingerprint sensing
US9720541B2 (en) 2015-06-30 2017-08-01 Synaptics Incorporated Arrangement of sensor pads and display driver pads for input device
CN205028263U (zh) 2015-09-07 2016-02-10 辛纳普蒂克斯公司 一种电容传感器
US10037112B2 (en) 2015-09-30 2018-07-31 Synaptics Incorporated Sensing an active device'S transmission using timing interleaved with display updates
US10067587B2 (en) 2015-12-29 2018-09-04 Synaptics Incorporated Routing conductors in an integrated display device and sensing device
CN106933400B (zh) 2015-12-31 2021-10-29 辛纳普蒂克斯公司 单层传感器图案和感测方法
WO2018071814A1 (en) 2016-10-14 2018-04-19 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
RU2760993C1 (ru) * 2021-02-15 2021-12-02 Сергей Александрович Никитин Способ рентгеновской терапии рака легких

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740463A (en) * 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US4748022A (en) * 1985-03-25 1988-05-31 Busciglio John A Topical composition
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US5055400A (en) * 1986-11-26 1991-10-08 University Of Guelph Leukotoxin gene of pasteurella haemolytica
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5532220A (en) * 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
US5017524A (en) * 1989-02-13 1991-05-21 Iscar Ltd. Ceramic cutting tool
US5362623A (en) * 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
US6800617B1 (en) * 1989-03-29 2004-10-05 The Johns Hopkins University Methods for restoring wild-type p53 gene function
US5527676A (en) * 1989-03-29 1996-06-18 The Johns Hopkins University Detection of loss of the wild-type P53 gene and kits therefor
US6677312B1 (en) * 1989-03-29 2004-01-13 The Johns Hopkins University Methods for restoring wild-type p53 gene function
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2108144A1 (en) * 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
TW442569B (en) * 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
ATE336587T1 (de) * 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien

Also Published As

Publication number Publication date
AU1126397A (en) 1997-06-19
ATE325872T1 (de) 2006-06-15
KR19990071795A (ko) 1999-09-27
SK70598A3 (en) 1999-04-13
HUP9902068A2 (hu) 1999-10-28
AU722042B2 (en) 2000-07-20
CN1308450C (zh) 2007-04-04
CN1207771A (zh) 1999-02-10
EP0863984A1 (en) 1998-09-16
DE69636120T2 (de) 2006-11-30
EP0863984B1 (en) 2006-05-10
DK0863984T3 (da) 2006-08-28
RU2174409C2 (ru) 2001-10-10
US20030166603A1 (en) 2003-09-04
CN101028523A (zh) 2007-09-05
ES2264145T3 (es) 2006-12-16
JP2000501394A (ja) 2000-02-08
WO1997020047A1 (en) 1997-06-05
NO982481D0 (no) 1998-05-29
US20020077313A1 (en) 2002-06-20
PL327009A1 (en) 1998-11-09
NZ324168A (en) 2004-11-26
US20060035857A1 (en) 2006-02-16
HUP9902068A3 (en) 2001-02-28
CA2238829A1 (en) 1997-06-05
CZ165798A3 (cs) 1998-12-16
DE69636120D1 (de) 2006-06-14
PL186018B1 (pl) 2003-09-30
CZ296810B6 (cs) 2006-06-14

Similar Documents

Publication Publication Date Title
NO982481L (no) Fremgangsmater og blandinger for diagnose og behandling av kreft
ATE238555T1 (de) Krebsbehandlung
DK1014996T3 (da) Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser
MY124091A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
WO1999031240A3 (en) 14-3-3σ ARRESTS THE CELL CYCLE
DE69936780D1 (de) Antikörper gegen eine lar-phosphatase untereinheit
AU5729098A (en) Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
CA2310888A1 (en) Monoclonal human natural antibodies
AU1808488A (en) Compounds for the treatment of alzheimer's disease
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
AU9779498A (en) Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
CA2373794A1 (en) Compositions and uses of et743 for treating cancer
NZ504419A (en) The use of carvedilol for treating amyloid diseases such as Alzheimer's
CA2281807A1 (en) Method of treating a tumor
BR0308896A (pt) complexos e hìbridos envelope do hiv-cd4
TR199801298T2 (xx) ACE-engelleyicinin dispeptik semptomlar�n tedavisinde yeni t�bbi kullan�m�.
GR3017967T3 (en) Substituted pyrido-oxazines.
EP1013642A3 (de) Chelatoren sowie deren Tricarbonyl-Komplexe mit Technetium und Rhenium
EP0278467A3 (en) Use of oxoquinazoline derivatives in the treatment of hyperuricemia
Veligotsky et al. Modern methods in treatment of patients with purulent vulneric processes
AU1721797A (en) Process for determining the phototoxicity and/or photosensitivity of substances or mixtures thereof, and use thereof
NO910642D0 (no) Diagnostisk middel som inneholder episialokompleks-karbohydrat og anvendelse derav ved paavisning av kreft.
Grünwald Low-grade lymphomas
邵长庚 et al. CURRENT TREATMENT OF VITILIGO IN CHINA
김규식 et al. The treatment and prognosis of benign fibro-osseous lesions of jaw

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application